exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088382 RNA Name: hsa-miR-423-5p RNA Type: miRNA Chromosome: chr17 Starnd: + Coordinate: Start Site(bp): 30117095 End Site(bp): 30117117 External Links: hsa-miR-423-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand DCAF7 chr17 63550477 63594279 + PGAM1 chr10 97426191 97433444 + MINK1 chr17 4833340 4898061 + PSME3 chr17 42824385 42843760 + LIMD2 chr17 63695888 63701172 - SYVN1 chr11 65121780 65134533 - KLC2 chr11 66257294 66267860 + MYBL2 chr20 43667019 43716495 + DLGAP4 chr20 36306336 36528637 + CAPN15 chr16 527712 554636 + MAPKBP1 chr15 41774434 41827855 + PAK2 chr3 196739857 196832647 + ACTN4 chr19 38647649 38731589 + C1QTNF6 chr22 37180166 37199385 - MAPK8IP2 chr22 50600793 50613981 + BCORL1 chrX 129981107 130058083 + FAM83H chr8 143723933 143738234 - WDR45B chr17 82614562 82648553 - CDCA7 chr2 173354820 173368997 + PRR12 chr19 49591182 49626439 + CHP1 chr15 41230839 41281887 + TNFAIP3 chr6 137867214 137883312 + IL2RB chr22 37125843 37175054 - RAB8A chr19 16111889 16134234 + HNRNPA2B1 chr7 26173057 26201529 - ATN1 chr12 6924463 6942321 + EIF5AL1 chr10 79512601 79516440 + IGF2BP1 chr17 48997385 49056145 + PPDPF chr20 63520765 63522206 + CTSD chr11 1752755 1764573 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001472 chr5 36953719 36976504 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC016876.2 chr17 7581964 7584086 - AC021078.1 chr5 149494314 149504670 - AL356488.2 chr1 109100193 109100619 + H19 chr11 1995176 2001470 - KCNQ1OT1 chr11 2608328 2699994 - MIR663AHG chr20 26167817 26251546 - MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.